In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme

Glioblastoma is an aggressive tumor with poor survival rates. Bispecific T cell engagers (BTEs) against different cancers are in various stages of clinical development. Toxicity resulting from cytokine release syndrome and the short half-life of BTEs, which necessitates continuous infusion, complica...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhojnagarwala, Pratik S., O’Connell, Ryan P., Park, Daniel, Liaw, Kevin, Ali, Ali R., Bordoloi, Devivasha, Cassel, Joel, Tursi, Nicholas J., Gary, Ebony, Weiner, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418050/
https://www.ncbi.nlm.nih.gov/pubmed/36090479
http://dx.doi.org/10.1016/j.omto.2022.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418050/
https://www.ncbi.nlm.nih.gov/pubmed/36090479
http://dx.doi.org/10.1016/j.omto.2022.07.003

Ejemplares similares